Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial

Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048

Abstract

Metadata

Authors/Creators:
  • Schey, S
  • Brown, SR
  • Tillotson, A-L
  • Yong, K
  • Williams, C
  • Davies, F
  • Morgan, G
  • Cavenagh, J
  • Cook, G
  • Cook, M
  • Orti, G
  • Morris, C
  • Sherratt, D
  • Flanagan, L
  • Gregory, W
  • Cavet, J
Keywords: myeloma; dosing; phase 2; bendamustine; relapsed-refractory
Dates:
  • Published: August 2015
  • Accepted: 16 February 2015
  • Published (online): 20 April 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Jul 2016 15:21
Last Modified: 03 Nov 2016 18:57
Published Version: http://dx.doi.org/10.1111/bjh.13435
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1111/bjh.13435
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics